Polaris Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Polaris Pharmaceuticals's estimated annual revenue is currently $7.2M per year.
- Polaris Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Polaris Pharmaceuticals has 36 Employees.
- Polaris Pharmaceuticals grew their employee count by -12% last year.
Polaris Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP Medical Affairs | Reveal Email/Phone |
3 | VP Clinical Affairs | Reveal Email/Phone |
4 | SVP Research & Development | Reveal Email/Phone |
5 | Head Technical Operations | Reveal Email/Phone |
6 | VP Regulatory Affairs ◂ Senior Director Regulatory Affairs | Reveal Email/Phone |
7 | Director Facilities | Reveal Email/Phone |
8 | Director, Environmental Health Safety | Reveal Email/Phone |
9 | Associate Director, Pharmacovigilance | Reveal Email/Phone |
10 | Sr. Director Quality and Compliance | Reveal Email/Phone |
Polaris Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Polaris Pharmaceuticals?
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.
keywords:N/A
N/A
Total Funding
36
Number of Employees
$7.2M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.1M | 36 | 9% | N/A |
#2 | $4.2M | 36 | N/A | N/A |
#3 | $8.9M | 36 | N/A | N/A |
#4 | $4.2M | 36 | -3% | N/A |
#5 | $7.5M | 36 | -3% | N/A |